文献速递前列腺增生与排尿功能障碍

二甲双胍在膀胱过度活动症中的应用:一项基于人群的回顾性巢式病例对照分析

The Use of Metformin in Overactive Bladder: A Retrospective Nested Case-control, Population-based Analysis.
PubMed 文献 · Urology · 2023-10-05

该研究利用基于人群的医疗行政数据库开展回顾性巢式病例对照研究,纳入年龄≥69岁的2型糖尿病患者,评估二甲双胍使用与膀胱过度活动症(OAB)药物处方的关联。结果显示二甲双胍使用与OAB药物使用呈正相关(调整比值比=1.07,95%CI=1.03-1.12),仅在二甲双胍累计供应天数超过2220天后无关联,提示在该人群中二甲双胍对OAB预防无保护作用。

要点

  • 在≥69岁2型糖尿病患者中,二甲双胍使用与OAB药物处方呈正相关(调整比值比=1.07,95%CI=1.03-1.12)。
  • 二甲双胍累计供应天数与OAB药物使用相关,但累计天数>2220天时无关联。
  • 作者认为在该患者人群中二甲双胍对OAB预防无保护作用。

核心结论

  • 作者结论:接受二甲双胍治疗的老年2型糖尿病患者OAB药物使用率略高,直至二甲双胍累计供应天数达2220天以上时无关联,提示在该人群中二甲双胍对OAB预防无保护作用。

研究设计与样本

  • 回顾性巢式病例对照研究,使用基于人群的医疗行政数据库。
  • 队列为年龄≥69岁的2型糖尿病患者,共2,233,084例。
  • 病例为接受OAB药物处方的患者,共16,549例,按年龄、性别和2型糖尿病诊断日期匹配最多4名对照,共64,171名匹配对照。
  • 暴露为在接受OAB药物之前新开具二甲双胍处方。
  • 使用条件逻辑回归估计调整比值比,并进行敏感性分析评估二甲双胍累计供应天数与OAB药物使用的关系。

主要发现

  • 二甲双胍使用与OAB药物使用呈正相关,调整比值比=1.07,95%CI=1.03-1.12。
  • 二甲双胍累计供应天数与OAB药物使用相关,但累计二甲双胍天数>2220天时无关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine if metformin use is associated with a lower rate of overactive bladder (OAB) medication use. Metformin facilitates the proliferation and migration of stem cells, which have been shown to improve bladder overactivity in animal models. METHODS: We conducted a retrospective nested case-control cohort study using population-based health-care administrative databases. Our cohort included patients with diabetes mellitus type 2 (DM2) ≥69years. Cases received a prescription for an OAB medication, matched with up to 4 controls based on age, sex, and DM2 diagnosis date. Exposure was a new prescription for metformin prior to receiving an OAB medication. Adjusted odds ratios were estimated using conditional logistic regression. Sensitivity analysis was done to assess the relationship between cumulative days' supply of metformin and use of OAB medications. RESULTS: Within our cohort of 2,233,084 patients with DM2, there were 16,549 case subjects who received a prescription for an OAB medication, and 64,171 matched controls. We found a positive association between OAB medication use and metformin use (adjusted odds ratios=1.07, 95% CI=1.03-1.12). Summed days' supply of metformin was also associated with OAB medication use, except when summed metformin days was >2220. CONCLUSION: Older patients with DM2 exposed to metformin had a slightly higher rate of OAB medication use, until 2220+ days' metformin supply, whereafter no association was found. This suggests no protective role for metformin in the prevention of OAB in this patient population.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Neu S, Matta R, Locke JA, et al. The Use of Metformin in Overactive Bladder: A Retrospective Nested Case-control, Population-based Analysis. Urology. 2023. PMID: 37805050. doi:10.1016/j.urology.2023.09.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。